Report cover image

Global Human iPSCs Market Analysis and Forecast 2025-2031

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 191 Pages
SKU # APRC20362373

Description

Summary

According to APO Research, The global Human iPSCs market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Human iPSCs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Human iPSCs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Human iPSCs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Human iPSCs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Human iPSCs include Sumitomo Dainippon Pharma, ReproCELL, Pluricell Biotech, Ncardia, Fujifilm Holding Corporation (CDI), Fate Therapeutics, Inc, Cell Inspire Biotechnology and Astellas Pharma Inc, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Human iPSCs, market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Human iPSCs, also provides the revenue of main regions and countries. Of the upcoming market potential for Human iPSCs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Human iPSCs revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Human iPSCs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for Human iPSCs revenue, projected growth trends, production technology, application and end-user industry.

Human iPSCs Segment by Company

Sumitomo Dainippon Pharma
ReproCELL
Pluricell Biotech
Ncardia
Fujifilm Holding Corporation (CDI)
Fate Therapeutics, Inc
Cell Inspire Biotechnology
Astellas Pharma Inc
Human iPSCs Segment by Type

Skin
Blood Cells
Human iPSCs Segment by Application

Regenerative Medicine
Drug Development and Discovery
Academic Research
Toxicity Screening
Others
Human iPSCs Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human iPSCs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Human iPSCs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human iPSCs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Human iPSCs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Human iPSCs company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Human iPSCs revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.

Table of Contents

191 Pages
1 Market Overview
1.1 Product Definition
1.2 Human iPSCs Market by Type
1.2.1 Global Human iPSCs Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Skin
1.2.3 Blood Cells
1.3 Human iPSCs Market by Application
1.3.1 Global Human iPSCs Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Regenerative Medicine
1.3.3 Drug Development and Discovery
1.3.4 Academic Research
1.3.5 Toxicity Screening
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Human iPSCs Market Dynamics
2.1 Human iPSCs Industry Trends
2.2 Human iPSCs Industry Drivers
2.3 Human iPSCs Industry Opportunities and Challenges
2.4 Human iPSCs Industry Restraints
3 Global Growth Perspective
3.1 Global Human iPSCs Market Perspective (2020-2031)
3.2 Global Human iPSCs Growth Trends by Region
3.2.1 Global Human iPSCs Market Size by Region: 2020 VS 2024 VS 2031
3.2.2 Global Human iPSCs Market Size by Region (2020-2025)
3.2.3 Global Human iPSCs Market Size by Region (2026-2031)
4 Competitive Landscape by Players
4.1 Global Human iPSCs Revenue by Players
4.1.1 Global Human iPSCs Revenue by Players (2020-2025)
4.1.2 Global Human iPSCs Revenue Market Share by Players (2020-2025)
4.1.3 Global Human iPSCs Players Revenue Share Top 10 and Top 5 in 2024
4.2 Global Human iPSCs Key Players Ranking, 2023 VS 2024 VS 2025
4.3 Global Human iPSCs Key Players Headquarters & Area Served
4.4 Global Human iPSCs Players, Product Type & Application
4.5 Global Human iPSCs Players Establishment Date
4.6 Market Competitive Analysis
4.6.1 Global Human iPSCs Market CR5 and HHI
4.6.3 2024 Human iPSCs Tier 1, Tier 2, and Tier 3
5 Human iPSCs Market Size by Type
5.1 Global Human iPSCs Revenue by Type (2020 VS 2024 VS 2031)
5.2 Global Human iPSCs Revenue by Type (2020-2031)
5.3 Global Human iPSCs Revenue Market Share by Type (2020-2031)
6 Human iPSCs Market Size by Application
6.1 Global Human iPSCs Revenue by Application (2020 VS 2024 VS 2031)
6.2 Global Human iPSCs Revenue by Application (2020-2031)
6.3 Global Human iPSCs Revenue Market Share by Application (2020-2031)
7 Company Profiles
7.1 Sumitomo Dainippon Pharma
7.1.1 Sumitomo Dainippon Pharma Comapny Information
7.1.2 Sumitomo Dainippon Pharma Business Overview
7.1.3 Sumitomo Dainippon Pharma Human iPSCs Revenue and Gross Margin (2020-2025)
7.1.4 Sumitomo Dainippon Pharma Human iPSCs Product Portfolio
7.1.5 Sumitomo Dainippon Pharma Recent Developments
7.2 ReproCELL
7.2.1 ReproCELL Comapny Information
7.2.2 ReproCELL Business Overview
7.2.3 ReproCELL Human iPSCs Revenue and Gross Margin (2020-2025)
7.2.4 ReproCELL Human iPSCs Product Portfolio
7.2.5 ReproCELL Recent Developments
7.3 Pluricell Biotech
7.3.1 Pluricell Biotech Comapny Information
7.3.2 Pluricell Biotech Business Overview
7.3.3 Pluricell Biotech Human iPSCs Revenue and Gross Margin (2020-2025)
7.3.4 Pluricell Biotech Human iPSCs Product Portfolio
7.3.5 Pluricell Biotech Recent Developments
7.4 Ncardia
7.4.1 Ncardia Comapny Information
7.4.2 Ncardia Business Overview
7.4.3 Ncardia Human iPSCs Revenue and Gross Margin (2020-2025)
7.4.4 Ncardia Human iPSCs Product Portfolio
7.4.5 Ncardia Recent Developments
7.5 Fujifilm Holding Corporation (CDI)
7.5.1 Fujifilm Holding Corporation (CDI) Comapny Information
7.5.2 Fujifilm Holding Corporation (CDI) Business Overview
7.5.3 Fujifilm Holding Corporation (CDI) Human iPSCs Revenue and Gross Margin (2020-2025)
7.5.4 Fujifilm Holding Corporation (CDI) Human iPSCs Product Portfolio
7.5.5 Fujifilm Holding Corporation (CDI) Recent Developments
7.6 Fate Therapeutics, Inc
7.6.1 Fate Therapeutics, Inc Comapny Information
7.6.2 Fate Therapeutics, Inc Business Overview
7.6.3 Fate Therapeutics, Inc Human iPSCs Revenue and Gross Margin (2020-2025)
7.6.4 Fate Therapeutics, Inc Human iPSCs Product Portfolio
7.6.5 Fate Therapeutics, Inc Recent Developments
7.7 Cell Inspire Biotechnology
7.7.1 Cell Inspire Biotechnology Comapny Information
7.7.2 Cell Inspire Biotechnology Business Overview
7.7.3 Cell Inspire Biotechnology Human iPSCs Revenue and Gross Margin (2020-2025)
7.7.4 Cell Inspire Biotechnology Human iPSCs Product Portfolio
7.7.5 Cell Inspire Biotechnology Recent Developments
7.8 Astellas Pharma Inc
7.8.1 Astellas Pharma Inc Comapny Information
7.8.2 Astellas Pharma Inc Business Overview
7.8.3 Astellas Pharma Inc Human iPSCs Revenue and Gross Margin (2020-2025)
7.8.4 Astellas Pharma Inc Human iPSCs Product Portfolio
7.8.5 Astellas Pharma Inc Recent Developments
8 North America
8.1 North America Human iPSCs Revenue (2020-2031)
8.2 North America Human iPSCs Revenue by Type (2020-2031)
8.2.1 North America Human iPSCs Revenue by Type (2020-2025)
8.2.2 North America Human iPSCs Revenue by Type (2026-2031)
8.3 North America Human iPSCs Revenue Share by Type (2020-2031)
8.4 North America Human iPSCs Revenue by Application (2020-2031)
8.4.1 North America Human iPSCs Revenue by Application (2020-2025)
8.4.2 North America Human iPSCs Revenue by Application (2026-2031)
8.5 North America Human iPSCs Revenue Share by Application (2020-2031)
8.6 North America Human iPSCs Revenue by Country
8.6.1 North America Human iPSCs Revenue by Country (2020 VS 2024 VS 2031)
8.6.2 North America Human iPSCs Revenue by Country (2020-2025)
8.6.3 North America Human iPSCs Revenue by Country (2026-2031)
8.6.4 United States
8.6.5 Canada
9 Europe
9.1 Europe Human iPSCs Revenue (2020-2031)
9.2 Europe Human iPSCs Revenue by Type (2020-2031)
9.2.1 Europe Human iPSCs Revenue by Type (2020-2025)
9.2.2 Europe Human iPSCs Revenue by Type (2026-2031)
9.3 Europe Human iPSCs Revenue Share by Type (2020-2031)
9.4 Europe Human iPSCs Revenue by Application (2020-2031)
9.4.1 Europe Human iPSCs Revenue by Application (2020-2025)
9.4.2 Europe Human iPSCs Revenue by Application (2026-2031)
9.5 Europe Human iPSCs Revenue Share by Application (2020-2031)
9.6 Europe Human iPSCs Revenue by Country
9.6.1 Europe Human iPSCs Revenue by Country (2020 VS 2024 VS 2031)
9.6.2 Europe Human iPSCs Revenue by Country (2020-2025)
9.6.3 Europe Human iPSCs Revenue by Country (2026-2031)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Netherlands
10 China
10.1 China Human iPSCs Revenue (2020-2031)
10.2 China Human iPSCs Revenue by Type (2020-2031)
10.2.1 China Human iPSCs Revenue by Type (2020-2025)
10.2.2 China Human iPSCs Revenue by Type (2026-2031)
10.3 China Human iPSCs Revenue Share by Type (2020-2031)
10.4 China Human iPSCs Revenue by Application (2020-2031)
10.4.1 China Human iPSCs Revenue by Application (2020-2025)
10.4.2 China Human iPSCs Revenue by Application (2026-2031)
10.5 China Human iPSCs Revenue Share by Application (2020-2031)
11 Asia (Excluding China)
11.1 Asia Human iPSCs Revenue (2020-2031)
11.2 Asia Human iPSCs Revenue by Type (2020-2031)
11.2.1 Asia Human iPSCs Revenue by Type (2020-2025)
11.2.2 Asia Human iPSCs Revenue by Type (2026-2031)
11.3 Asia Human iPSCs Revenue Share by Type (2020-2031)
11.4 Asia Human iPSCs Revenue by Application (2020-2031)
11.4.1 Asia Human iPSCs Revenue by Application (2020-2025)
11.4.2 Asia Human iPSCs Revenue by Application (2026-2031)
11.5 Asia Human iPSCs Revenue Share by Application (2020-2031)
11.6 Asia Human iPSCs Revenue by Country
11.6.1 Asia Human iPSCs Revenue by Country (2020 VS 2024 VS 2031)
11.6.2 Asia Human iPSCs Revenue by Country (2020-2025)
11.6.3 Asia Human iPSCs Revenue by Country (2026-2031)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 Taiwan
11.6.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA Human iPSCs Revenue (2020-2031)
12.2 SAMEA Human iPSCs Revenue by Type (2020-2031)
12.2.1 SAMEA Human iPSCs Revenue by Type (2020-2025)
12.2.2 SAMEA Human iPSCs Revenue by Type (2026-2031)
12.3 SAMEA Human iPSCs Revenue Share by Type (2020-2031)
12.4 SAMEA Human iPSCs Revenue by Application (2020-2031)
12.4.1 SAMEA Human iPSCs Revenue by Application (2020-2025)
12.4.2 SAMEA Human iPSCs Revenue by Application (2026-2031)
12.5 SAMEA Human iPSCs Revenue Share by Application (2020-2031)
12.6 SAMEA Human iPSCs Revenue by Country
12.6.1 SAMEA Human iPSCs Revenue by Country (2020 VS 2024 VS 2031)
12.6.2 SAMEA Human iPSCs Revenue by Country (2020-2025)
12.6.3 SAMEA Human iPSCs Revenue by Country (2026-2031)
12.6.4 Brazil
12.6.5 Argentina
12.6.6 Chile
12.6.7 Colombia
12.6.8 Peru
12.6.9 Saudi Arabia
12.6.10 Israel
12.6.11 UAE
12.6.12 Turkey
12.6.13 Iran
12.6.14 Egypt
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.